The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction

References

• GacciMEardleyIGiulianoFCritical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasiaEur Urol201160480982521726934
   PubMed Web of Science ®Google Scholar
• GacciMCoronaGSalviMA systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasiaEur Urol2012615994100322405510
   PubMed Web of Science ®Google Scholar
• MacfarlaneGJBottoHSagnierPPTeillacPRichardFBoylePThe relationship between sexual life and urinary condition in the French communityJ Clin Epidemiol19964910117111768826998
   PubMed Web of Science ®Google Scholar
• LaumannEOPaikARosenRCSexual dysfunction in the United States: prevalence and predictorsJAMA1999281653754410022110
   PubMed Web of Science ®Google Scholar
• BlankerMHBohnenAMGroeneveldFPCorrelates for erectile and ejaculatory dysfunction in older Dutch men: a community-based studyJ Am Geriatr Soc200149443644211347788
   PubMed Web of Science ®Google Scholar
• LiMKGarciaLARosenRLower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countriesBJU Int20059691339135416287456
   PubMed Web of Science ®Google Scholar
• BrookesSTLinkCLDonovanJLMcKinlayJBRelationship between lower urinary tract symptoms and erectile dysfunction: results from the Boston Area Community Health SurveyJ Urol2008179125025518001787
   PubMed Web of Science ®Google Scholar
• SakSCHussainZJohnstonCEardleyIWhat is the relationship between male sexual function and lower urinary tract symptoms (LUTS)?Eur Urol200446448248715363565
   PubMed Web of Science ®Google Scholar
• RosenRAltweinJBoylePLower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)Eur Urol200344663764914644114
   PubMed Web of Science ®Google Scholar
• WeinAJCoyneKSTubaroASextonCCKoppZSAiyerLPThe impact of lower urinary tract symptoms on male sexual health: EpiLUTSBJU Int2009103Suppl 3334119302500
   PubMed Web of Science ®Google Scholar
• BouwmanIIVan Der HeideWKVan Der MeerKNijmanRCorrelations between lower urinary tract symptoms, erectile dysfunction, and cardiovascular diseases: are there differences between male populations from primary healthcare and urology clinics? A review of the current knowledgeEur J Gen Pract200915312813519958261
   PubMed Web of Science ®Google Scholar
• AnderssonKEde GroatWCMcVaryKTTadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of actionNeurourol Urodyn201130329230121284024
   PubMed Web of Science ®Google Scholar
• FilippiSMorelliASandnerPCharacterization and functional role of androgen-dependent PDE5 activity in the bladderEndocrinology200714831019102917138653
   PubMed Web of Science ®Google Scholar
• FibbiBMorelliAVignozziLCharacterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tractJ Sex Med201071 Pt 1596919796053
   PubMed Web of Science ®Google Scholar
• MorelliAFilippiSComeglioPAcute vardenafil administration improves bladder oxygenation in spontaneously hypertensive ratsJ Sex Med201071 Pt 110712019889145
   PubMed Web of Science ®Google Scholar
• MorelliASarchielliEComeglioPPhosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive ratsJ Sex Med20118102746276021812935
   PubMed Web of Science ®Google Scholar
• VignozziLFilippiSMorelliACavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadismJ Sex Med2009651270128319210708
   PubMed Web of Science ®Google Scholar
• AnguloJCuevasPFernándezATadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neckJ Sex Med2012992293230622759598
   PubMed Web of Science ®Google Scholar
• MorelliAFilippiSSandnerPVardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive ratsJ Sex Med2009661594160819473460
   PubMed Web of Science ®Google Scholar
• GacciMDel PopoloGMacchiarellaAVardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot studyJ Urol200717852040204317869296
   PubMed Web of Science ®Google Scholar
• GacciMIerardiARoseADVardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot studyJ Sex Med201071 Pt 123424319732303
   PubMed Web of Science ®Google Scholar
• FibbiBPennaGMorelliAAdoriniLMaggiMChronic inflammation in the pathogenesis of benign prostatic hyperplasiaInt J Androl201033347548819508330
   PubMedGoogle Scholar
• GacciMVignozziLSebastianelliAMetabolic syndrome and lower urinary tract symptoms: the role of inflammationProstate Cancer Prostatic Dis Epub11202012
   Web of Science ®Google Scholar
• KramerGMittereggerDMarbergerMIs benign prostatic hyperplasia (BPH) an immune inflammatory disease?Eur Urol20075151202121617182170
   PubMed Web of Science ®Google Scholar
• FilippiSVignozziLMorelliATestosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndromeJ Sex Med20096123274328819732305
   PubMed Web of Science ®Google Scholar
• VignozziLMorelliAFilippiSFarnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetesJ Sex Med201181577720955313
   PubMed Web of Science ®Google Scholar
• VignozziLMorelliASarchielliETestosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbitJ Endocrinol20122121718422010203
   PubMed Web of Science ®Google Scholar
• MorelliAComeglioPFilippiSMechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbitProstate201273442844122996758
   PubMed Web of Science ®Google Scholar
• MorelliAComeglioPFilippiSTestosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndromeJ Steroid Biochem Mol Biol20121321–2809222406511
   PubMed Web of Science ®Google Scholar
• ManeschiEMorelliAFilippiSTestosterone treatment improves metabolic syndrome-induced adipose tissue derangementsJ Endocrinol2012215334736223045189
   PubMed Web of Science ®Google Scholar
• ZenzmaierCSampsonNPernkopfDPlasEUntergasserGBergerPAttenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasiaEndocrinology201015183975398420555034
   PubMed Web of Science ®Google Scholar
• PennaGMondainiNAmuchasteguiSSeminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasiaEur Urol200751252453316905241
   PubMed Web of Science ®Google Scholar
• McVaryKTRoehrbornCGAvinsALUpdate on AUA guideline on the management of benign prostatic hyperplasiaJ Urol201118551793180321420124
   PubMed Web of Science ®Google Scholar
• HutchisonAFarmerRVerhammeKBergesRNavarreteRVThe efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countriesEur Urol2007511207215 discussion 215–21616846678
   PubMed Web of Science ®Google Scholar
• DebruyneFKochGBoylePComparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international studyEur Urol200241549750612074791
   PubMed Web of Science ®Google Scholar
• ZlottaARTeillacPRaynaudJPSchulmanCCEvaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or FinasterideEur Urol200548226927615939527
   PubMed Web of Science ®Google Scholar
• ChappleCRMontorsiFTammelaTLWirthMKoldewijnEFernández FernándezEEuropean Silodosin Study GroupSilodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in EuropeEur Urol201159334235221109344
   PubMed Web of Science ®Google Scholar
• NickelJCFradetYBoakeRCEfficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year StudyCMAJ19961559125112598911291
   PubMed Web of Science ®Google Scholar
• RoehrbornCGSiamiPBarkinJCombAT Study GroupThe effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT studyEur Urol201057112313119825505
   PubMed Web of Science ®Google Scholar
• McVaryKTRoehrbornCGAvinsALGuideline on the management of benign prostatic hyperplasia (BPH)American Urological Association Guideline: Management of BPHBaltimore, MDAmerican Urological Association Education and Research2003
   Google Scholar
• BouzaCLópezTMagroANavalpotroLAmateJMSystematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic HyperplasiaBMC Urol200661416790044
   PubMedGoogle Scholar
• OelkeMBachmannADescazeaudAEAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms, including benign prostatic obstructionEur Urol2013 [Epub ahead of print. March 2013]
   Web of Science ®Google Scholar
• RoehrbornCGStandard surgical interventions: TURP/TUIP/OPSUKirbyRSMcConnellJDFitzpatrickJMRoehrbornCGBoylePTextbook of Benign Prostatic HyperplasiaOxfordISIS Medical Media1996341378
   Google Scholar
• BrigantiANasproRGallinaAImpact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trialJ Urol200617551817182116600770
   PubMed Web of Science ®Google Scholar
• McVaryKTRoehrbornCGKaminetskyJCTadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasiaJ Urol200717741401140717382741
   PubMed Web of Science ®Google Scholar
• RoehrbornCGMcVaryKTElion-MboussaAViktrupLTadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding studyJ Urol200818041228123418722631
   PubMed Web of Science ®Google Scholar
• BecharaARomanoSCasabéAComparative efficacy assessment of tamsulosin vs tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot studyJ Sex Med2008592170217818638006
   PubMed Web of Science ®Google Scholar
• LiguoriGTrombettaCDe GiorgiGEfficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary reportJ Sex Med20096254455219138360
   PubMed Web of Science ®Google Scholar
• PorstHMcVaryKTMontorsiFEffects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasiaEur Urol200956472773519409693
   PubMed Web of Science ®Google Scholar
• RoehrbornCGKaminetskyJCAuerbachSMMontelongoRMElion-MboussaAViktrupLChanges in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatmentBJU Int2010105450250719732051
   PubMed Web of Science ®Google Scholar
• DmochowskiRRoehrbornCKliseSXuLKaminetskyJKrausSUrodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trialJ Urol201018331092109720092847
   PubMed Web of Science ®Google Scholar
• PorstHKimEDCasabéARLVHJ study teamEfficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trialEur Urol20116051105111321871706
   PubMed Web of Science ®Google Scholar
• DonatucciCFBrockGBGoldfischerERTadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension studyBJU Int201110771110111621244606
   PubMed Web of Science ®Google Scholar
• OelkeMGiulianoFMironeVXuLCoxDViktrupLMonotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trialEur Urol201261591792522297243
   PubMed Web of Science ®Google Scholar
• RegadasRPRegesRCerqueiraJBUrodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trialInt Urol Nephrol2012451394323108604
   PubMed Web of Science ®Google Scholar
• YokoyamaOYoshidaMKimSCTadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian menInt J Urol Epub2012972012
   Google Scholar
• LiuLZhengSHanPWeiQPhosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysisUrology201177112312921195830
   PubMed Web of Science ®Google Scholar
• Martínez-SalamancaJICarballidoJEardleyIPhosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidenceEur Urol201160352753521684677
   PubMed Web of Science ®Google Scholar